UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Summary of changes)

Authors

  • Andrea Kokorovic Centre Hospitalier de l’Université de Montréal
  • Alan I. So Department of Urological Sciences, University of British Columbia
  • Hosam Serag Department of Urological Sciences, University of British Columbia
  • Christopher French Division of Urology, Department of Surgery, Memorial University
  • Robert J. Hamilton Division of Urology, Department of Surgery, Princess Margaret Cancer Centre
  • Jason P. Izard Department of Urology, Queen’s University
  • Jasmir G. Nayak Section of Urology, Department of Surgery, University of Manitoba
  • Frédéric Pouliot CHU de Quebec, Université Laval
  • Fred Saad Centre Hospitalier de l’Université de Montréal
  • Bobby Shayegan Division of Urology, Departments of Surgery and Oncology, McMaster University
  • Armen Aprikian McGill University Health Centre
  • Ricardo A. Rendon Department of Urology, Dalhousie University

DOI:

https://doi.org/10.5489/cuaj.8007

Keywords:

ADT, prostate cancer, CVD risk

Downloads

Download data is not yet available.

Downloads

Published

2022-07-21

How to Cite

Kokorovic, A. ., So, A. I. ., Serag, H. ., French, C. ., Hamilton, R. J. ., Izard, J. P. ., … Rendon, R. A. . (2022). UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Summary of changes). Canadian Urological Association Journal, 16(8), 243–4. https://doi.org/10.5489/cuaj.8007

Issue

Section

CUA Guideline